DAFTAR PUSTAKA

1. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug – drug interactions with over-the-counter NSAIDs. 2015:1061-1075.
2. Hafsi K, McKay J, Li J, et al. Nutritional, metabolic and genetic considerations to optimise regenerative medicine outcome for knee *osteoarthritis*. *J Clin Orthop Trauma*. 2019;10(1):2-8. doi:10.1016/j.jcot.2018.10.004
3. Kesehatan K. *Hasil Utama Riskesdas 2018*.; 2018.
4. Dinas Kesehatan Provinsi Sumatera Barat. Profil Kesehatan Sumatera Barat Tahun 2013. 2014;(65).
5. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang. *Profil Kesehat Kota Padang*. 2017;(45).
6. Mardhiyah R, Fauzi A, Syam AF. Diagnosis dan Tata Laksana Enteropati akibat Obat Anti Inflamasi Non Steroid (OAINS). 2015;2(3):190-197.
7. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. *Aging Dis*. 2018;9(1):143. doi:10.14336/ad.2017.0306
8. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration ? 2001:1-4.
9. Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and clinical considerations. *J Pers Med*. 2018;8(1):1-31. doi:10.3390/jpm8010001
10. Dean L. Flurbiprofen Therapy and CYP2C9 Genotype. 2012;(Md):1-8.
11. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. *Clin Pharmacol Ther*. 2017;102(4):688-700. doi:10.1002/cpt.690
12. Trent RJ. DNA, RNA, Genes and Chromosomes. *Mol Med*. 2007;(C):17-I. doi:10.1016/b978-012699057-7/50002-3
13. Korf BR. Basic genetics. 2004;31:461-478. doi:10.1016/j.pop.2004.04.012
14. Ross DW, Ross DW. Gene Expression and Regulation. *Introd to Mol Med*. 2012:22-34. doi:10.1007/978-0-387-22521-0_2

15. Powledge TM. Genetic Basics. *Natl Institutes Heal*. 2001:1-70. www.nigms.nih.gov.
16. Dyer BD. *The Basic of Genetics*.; 2018.
17. J.Brooker R. *Concepts of Genetics*. McGraw-Hill Education; 2011.
18. Robinson R. *Genetics*. Arizona: Thomson Gale; 2003.
19. Kadakkuzha BM, Puthanveettil S V. Genomics and proteomics in solving brain complexity. *Mol Biosyst*. 2013;9(7):1807-1821. doi:10.1039/c3mb25391k
20. Herzyk P. *Handbook of Pharmacogenomics and Stratified Medicine*.; 2014. doi:10.1016/B978-0-12-386882-4.00008-6
21. Mallar KN, Prasenjit D. Single Nucleotide Polymorphism (SNP). :1-9.
22. March R. Pharmacogenomics: The Genomics of Drug Response. *Yeast*. 2002;1(1):16-21. doi:10.1002/(sici)1097-0061(200004)17:1<16::aid-yea6>3.0.co;2-e
23. Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. *Pharmacogenomics J*. 2012;12(6):462-467. doi:10.1038/tpj.2012.40
24. Brunton L, Chabner B, Knollman B. *The Pharmacological Basis of Therapeutics*.; 2011.
25. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochem Pharmacol*. 1997;54(1):33-41. doi:10.1016/S0006-2952(97)00143-3
26. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of cytochrome p450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clin Pharmacol Ther*. 2002;72(1):62-75. doi:10.1067/mcp.2002.125726
27. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the ctochrome P450 with NADPH:cytochrome P450 oxidoreductase. *Pharmacogenetics*. 1997;7(3):203-210. doi:10.1097/00008571-199706000-00005
28. Trager WF, Haining RL, Rushmore TH, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. *Pharmacogenetics*.

2006;7(5):361-367. doi:10.1097/00008571-199710000-00004

29. Al-obeidy MS, Ali TH. International Journal of Advanced Multidisciplinary Research Examining the Functional Roles of Street Characteristics in Influencing the Sense of Place. 2017;4:23-31. doi:10.22192/ijamr
30. Xue D, Zheng Q, Li H, Qian S, Zhang B, Pan Z. Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis of randomised trials. *Int Orthop*. 2011;35(1):3-8. doi:10.1007/s00264-009-0886-y
31. Johnston SA, McLaughlin RM, Budsberg SC. Nonsurgical Management of *Osteoarthritis* in Dogs. *Vet Clin North Am - Small Anim Pract*. 2008;38(6):1449-1470. doi:10.1016/j.cvsm.2008.08.001
32. Sara Calatayud, Esplugues JV. Chemistry, Pharmacodynamics, and Pharmacokinetics of NSAIDs. *Nurse Pract*. 2003;28(12):56. doi:10.1097/00006205-200312000-00011
33. Katzung BG. *Basic & Clinical Pharmacology*. 14th ed. EGC Penerbit Buku Kedokteran
34. WHO. *Osteoarthritis*, Priority disease and reason for inclusion. *World Heal Organ*. 2010;12:6-8. http://www.who.int/medicines/areas/priority_medicines/Ch6_12Osteo.pdf.
35. Kasper D, Fauci A, Longo D. *Harrison's Principles of Internal Medicine 20th Edition*. McGraw-Hill Education; 2018.
36. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res*. 2012;64(10):1431-1446. doi:10.1002/acr.21772
37. Jansen TL, Richette P, Perez-Ruiz F, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2016;76(1):29-42. doi:10.1136/annrheumdis-2016-209707
38. Papazoglou A, Gorbachova T, Brent LH. *Psoriatic arthritis: Pathogenesis,*

Clinical Features and Treatment.; 2016.

39. Nash P, Clegg DO. *Psoriatic arthritis* therapy: NSAIDs and traditional DMARDs. *Ann Rheum Dis*. 2005;64(SUPPL. 2):74-77. doi:10.1136/ard.2004.030783
40. Schett G. The Pathogenesis of *Rheumatoid arhtritis*. 2011:2205-2219. doi:10.1056/NEJMra1004965
41. Majithia V, Geraci SA. *Rheumatoid arhtritis*: Diagnosis and Management. *Am J Med*. 2007;120(11):936-939. doi:10.1016/j.amjmed.2007.04.005
42. Carlson S, Rauchenstein J. Hypertrophic Osteoarthropathy. *Resid Radiol*. 2009;115(12):W259-W272. doi:10.2214/AJR.09.3300.
43. White EA, Schein AJ, Matcuk GR, et al. Hypertrophic Osteoarthropathy: Clinical and Imaging Features. *RadioGraphics*. 2016;37(1):157-195. doi:10.1148/rg.2017160052
44. Galuppi E, Bortoluzzi A, Govoni M, Trotta F. Hypertrophic osteoarthropathy: classification, diagnostic features, and treatment options. *Expert Opin Orphan Drugs*. 2016;4(8):831-836. doi:10.1080/21678707.2016.1205481
45. Innes J. *Septic arthritis*. *Complicat Small Anim Surg*. 2017;3(4):34-38. doi:10.1002/9781119421344.ch6
46. Finding out your child has *Juvenile idiopathic arthritis* (JIA). *Arthritis New Zeal*.
47. Consolaro A, Lanni S, Schiappapietra B, Giancane G, Ravelli A, Davì S. *Juvenile idiopathic arthritis*: Diagnosis and Treatment. *Rheumatol Ther*. 2016;3(2):187-207. doi:10.1007/s40744-016-0040-4
48. Shah R, Perry L, Deodha A. The role of secukinumab in the treatment of *ankylosing spondylitis*. 2015.
49. Badyal DK et al. Cytochrome P450 and drug interactions. *Indian J Pharmacol*. 2001;33:248-259.
50. Guengerich FP. Rate-Limiting Steps in Cytochrome P450 Catalysis. *Biol Chem*. 2002;383(10):1553-1564. doi:10.1515/BC.2002.175
51. Niemi M. *Effects of Induction and Inhibition of Cytochrome P-450 Enzymes on the Pharmacokinetics and Pharmacodynamics of Oral*

Antidiabetic Drugs.; 2001.

52. Booven D Van, Marsh S, McLeod H, et al. Cytochrome P450 2C9-CYP2C9. *NIH Public Access*. 2010;20(4):277-281. doi:10.1097/FPC.0b013e3283349e84.Cytochrome
53. Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: Clinical implications. *Eur J Clin Pharmacol*. 2013;69(7):1369-1373. doi:10.1007/s00228-013-1477-9
54. Figueiras A, Estany-Gestal A, Aguirre C, et al. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: A case-control study. *Pharmacogenet Genomics*. 2016;26(2):66-73. doi:10.1097/FPC.0000000000000186
55. Desai H. Editorial: Dyspepsia. *Assoc Physicians India*. 2012;60.
56. Zagefka H. The concept of ethnicity in social psychological research: Definitional issues. *Int J Intercult Relations*. 2009;33(3):228-241. doi:10.1016/j.ijintrel.2008.08.001
57. Sukmawati N. Bagurau Saluang dan Dendang Dalam Perspektif Perubahan Budaya Minangkabau. *J Forum Ilmu Sos*. 2008;35(2).
58. Roman-Blas J, Castañeda S, Largo R, Herrero-Beaumont G. *Osteoarthritis* associated with estrogen deficiency. *Arthritis* Research & Therapy. 2009;11(5):241.
59. Štefanovic M, and Samardžija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2004;42(1):72-78.
60. Kementrian Kesehatan. KEPMENKES Nomor 328/ MENKES/ SK/ VIII/ 2013 tentang Formularium Nasional. 2013.
61. Horkovics-Kovats S. Efficiency of enterohepatic circulation, its determination and influence on drug bioavailability. *Arzneimittelforschung*. 1999;49(10):805-815.
62. Turesky RJ, et al. The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine in rats. *Chemico-biological interactions*. 2003;145(3):251-265.

63. Weathermon R, and Crabb DW. Alcohol and medication interactions. *Alcohol research*. 1999;23(1):40.
64. Saneei P, et al. "Relationship between spicy food intake and chronic uninvestigated dyspepsia in Iranian adults." *Journal of digestive diseases*. 2016:17(1):28-35.
65. U.S. Food and Drug Administration. Medication Guide for Nonsteroidal Anti-Inflammatory drugs (NSAIDs). New York: Pharmacia & Upjohn Company. 2016:3.
66. Harirforoosh S, Asghar W, and Jamali F. "Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications." *Journal of Pharmacy & Pharmaceutical Sciences*. 2014:16(5):821-847.
67. Moore RA, et al. Nonsteroidal Anti- Inflammatory Drugs, Gastroprotection, and Benefit–Risk. *Pain Practice*. 2014;14(4):378-395.
68. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol [Internet]. Januari 2004;141(2):205–8.Koziolek, Mirko, et al. The mechanisms of pharmacokinetic food-drug interactions–A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*. 2019;134:31-59.
69. Rosenberg LE, Rosenberg DD. Framing the Field. In: Human Genes and *Genome*s [Internet]. Elsevier; 2012. hal. 3–8.O'Malley, Meaghan, et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. *Journal of Thoracic Oncology* 9.7 (2014): 917-926.